Lumateperone: First Approval
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01271-6
Abstract: Lumateperone (Caplyta ® ) is a novel, orally available agent developed by Intra-Cellular Therapies (under a license from Bristol-Myers Squibb) for the treatment of schizophrenia and other neuropsychiatric and neurological disorders. Lumateperone is a first-in-class… read more here.
Keywords: first approval; lumateperone; lumateperone first; treatment schizophrenia ... See more keywords
Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia
Sign Up to like & getrecommendations! Published in 2018 at "Neuropsychopharmacology"
DOI: 10.1038/s41386-018-0251-1
Abstract: Dopamine D2 receptor occupancy (D2RO) is a key feature of all currently approved antipsychotic medications. However, antipsychotic efficacy associated with high D2RO is often limited by side effects such as motor disturbances and hyperprolactinemia. Lumateperone… read more here.
Keywords: iti 007; study; dopamine receptor; lumateperone ... See more keywords
T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
Sign Up to like & getrecommendations! Published in 2020 at "Schizophrenia Bulletin"
DOI: 10.1093/schbul/sbaa029.765
Abstract: Abstract Background Standard of care (SOC) antipsychotics exhibit efficacy at high dopamine D2 receptor occupancy (60%-80%), which is associated with increased risk of extrapyramidal symptoms (EPS). Lumateperone (lumateperone tosylate, ITI-007) is a mechanistically novel antipsychotic… read more here.
Keywords: schizophrenia; eps related; long term; treatment ... See more keywords
Adjunctive Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results From a Randomized Placebo-Controlled Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "Bipolar disorders"
DOI: 10.1111/bdi.13310
Abstract: OBJECTIVE This phase 3, randomized, double-blind, placebo-controlled study (NCT02600507) evaluated the efficacy and safety of lumateperone adjunctive therapy to lithium or valproate in patients with bipolar depression. METHODS Patients (18-75 years) with bipolar I or bipolar… read more here.
Keywords: adjunctive lumateperone; depression; lumateperone; placebo controlled ... See more keywords